| INTRODUCTION
The Golgi apparatus, composed of several compartments (cisternae), each characterized by the presence of a distinct set of Golgi-resident enzymes in a graded fashion, is a dynamic organelle that can alter its size and morphology in response to various intrinsic and extrinsic signals in a poorly understood fashion. 1 It fulfills several vital functions such as cargo processing (for instance, proteolytic cleavage, phosphorylation, glycosylation, sulfation) of proteins that have entered the secretory pathway, sorting of protein and lipids and initiation or propagation of signaling. 2 Before proteins reach the Golgi through vesicular transport, they are first folded and modified in the endoplasmic reticulum (ER). Perturbations to ER homeostasis can be elicited by various stress conditions including viral infection, hypoxia, glucose deprivation and imbalances in redox state or Ca 2+ levels, causing the accumulation of misfolded proteins in the ER lumen. This serves as upstream stress signal setting in motion an intertwined transduction cascade termed unfolded protein response (UPR). UPR-mediated inhibition of general protein synthesis, increased ER-associated degradation (ERAD) activity, expansion of ER volume and transcriptional upregulation of ER chaperones and other enzymes assisting in folding are amongst the processes controlled by the UPR. 3 During protracted ER stress, adaptive steps of the UPR are downregulated, while proapoptotic signaling is reinforced. 4 ER stress/UPR induction is found in tumors across multiple tissues in many instances correlating with poor patient prognosis or increased resistance to chemotherapy suggesting that therapeutically targeting the ER stress response either through ER stress overload or disruption of adaptive mechanisms could result in elimination of cancer cells. 5, 6 Accordingly, the development of drugs modulating branches of the UPR is an active field of investigation. 7 Given the close physical and functional connection between the Golgi and ER, it is surprising that the Golgi complex has remained largely uncharted territory as a drug intervention point.
Nonetheless, a number of structurally unrelated compounds with antineoplastic properties have been found to induce Golgi disorganization including collapse of the entire Golgi ribbon or only parts of it. However, no bona fide Golgi-specific molecule has been identified. [8] [9] [10] Golgi disruption has also been observed when cells were treated with FDA-approved drugs such as etoposide, doxorubicin or Sorafenib suggesting that interference with Golgi structure as novel strategy for anticancer treatment warrants further investigation. [11] [12] [13] Brefeldin A (BFA) was discovered in 1968 as a fungal metabolite derived from soil samples exhibiting antiviral and antifungal activities. 14 Since then, numerous reports have described BFA's protein trafficking-inhibitory and tumor-suppressive roles, but the high neurotoxicity, fast clearance from blood plasma after intravenous injection and unsatisfactory bioavailability effects hindered its further development into a drug useful in clinical settings. [15] [16] [17] BFA acts as uncompetitive inhibitor by binding into a hydrophobic pocket, which is generated only in the simultaneous presence of some members of the five mammalian ADP-ribosylation factor (ARF) guanosine triphosphatases (GTPases) in their inactive state (i. e., GDP bound) and their BFA-sensitive large guanine nucleotide exchange factors (GEFs), thereby locking the ARF/ARF-GEF complex in an unproductive conformation that prevents GDP for GTP nucleotide exchange. 18, 19 BFA treatment causes inhibition of protein secretion through the cessation of anterograde but not retrograde transport from the ER to the Golgi causing Golgi dispersal and tubulation of recycling endosomes, which mix with the trans-Golgi network. [20] [21] [22] In turn, this results in accumulation of Golgi-resident proteins in the ER consequently leading to UPR induction. More recently AMF-26 (also named M-COPA),
another Golgi-disrupting molecule, was shown to display promising anticancer activity in vitro and in vivo and may have a similar ARF1-inhibiting activity as BFA. However, the exact nature of the molecular entity targeted by AMF-26 was not unequivocally identified. 23, 24 The ARF family of small GTP-binding proteins control cargo sorting, transport of proteins and lipids along the secretory pathway, actin cytoskeleton organization or recruitment of coat polymers and lipid modifying enzymes to endomembranes. 25 Some ARF GTPases are overexpressed in certain cancers such as prostate and breast promoting invasion, migration or metastasis. [26] [27] [28] [29] [30] [31] [32] [33] [34] ARF1 is also implicated in the maintenance of cancer stem cell pools both in Drosophila as well as in mammals, and it regulates sensitivity of tumor cells to gefitinib suggesting that blocking ARF1 activity in certain cancers could improve therapeutic outcomes.
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Here, we explored AMF-26's effect on cell viability, Golgi morphology and secretory capacity and compared it to BFA using a panel of human cell lines. Next, we assessed whether significant associations exist between the extent of Golgi dispersal, survival ratio and protein transport in four selected cell lines in response to AMF-26 and BFA.
Negative concentration-dependent correlations between Golgi dispersal and viability or secretion, respectively, could be observed with Figures 1A and S1B ). These results were also validated by colony formation experiments performed with 6 selected cell lines ( Figure S1C ).
Of the 13 cell lines tested, sensitivity (IC 50 values) to AMF-26 or BFA varied between cell lines up to 30-and 100-fold, respectively ( Figure 1A ). Survival of cells in response to the compounds did not correlate with cell doubling times suggesting that other factors are responsible for differences in sensitivity between cell lines ( Figure S1D ). We found that the dose-response curves for AMF-26
and BFA are very similar in shape, however, a comparison of cell growth inhibition side-by-side for both drugs revealed a right shift of the growth curves for AMF-26-treated cells compared to BFA indicating that cells can tolerate AMF-26 better than BFA ( Figure S1B ). In line with previously published data, 23 our results point to a similar mechanism of cell killing for both drugs, which is also reflected by molecular similarity calculations ( Figure S1E ). To investigate signaling mechanisms triggered in response to AMF-26 and BFA treatment, we performed Western blot analysis of different proteins associated with the secretory pathway. Increased GRP78 could be observed with AMF-26 and BFA indicating that both compounds induce ER stress.
Moreover, GBF1 levels slightly increased in response to BFA as was also previously reported 36 as well as following AMF-26 treatment ( Figure 1B ). In support of the survival data, BFA induced higher GRP78 expression at equimolar concentrations compared with AMF-26. In addition, ARF4 expression, previously shown to be elicited by BFA-induced Golgi dispersal, 36 was also increased by AMF-26. Interestingly, opposite to ARF4, higher doses of AMF-26 or BFA caused a reduction in the levels of ARF1, ARF3 and ARF5 ( Figure 1B ; see also interactions. 19 We first checked by transient cotransfection assays Figure 1D ). Thus, our results suggest that similar to GCA, AMF-26 targets specifically the ARF-GBF1 complex but not ARF1-BIG1/2 in a manner mechanistically comparable to BFA but likely with lower affinity.
| AMF-26 and BFA disrupt the Golgi complex and inhibit secretion of Gaussia luciferase
Golgi morphology is important for cell metabolism and signaling. 2, 13 Disruption of the Golgi complex can lead to a block in secretory traffic and eventually to cell death. 41 We were interested to understand whether To test whether Golgi fragmentation as a result of exposure to AMF-26 or BFA had a functional impact on protein trafficking, we assessed secretion of a Gaussia-luciferase (GLuc) fusion protein reporter into the culture media. GLuc, derived from the marine Figure 2D ), A549 cells were treated with the same range of GCA concentrations for 72 hours, and growth inhibitory effects were measured using CTB. Survival ratios were calculated as described before.
copepod Gaussia princeps, is a small enzyme whose proper folding and secretion depends on the functionality of the Golgi apparatus. accelerates protein transport to the cell surface in HeLa cells due to cisternal unstacking but has negative consequences for protein glycosylation and sorting. 46 Another possibility is that in response to lower concentrations of AMF-26 or BFA transport of the GLuc reporter could also be partially mediated by unconventional protein secretion, a process that bypasses the Golgi complex and might aid in expediting secretion. [47] [48] [49] [50] In response to BFA and to a lesser extent to AMF- Finally we also tested a third small molecule inhibitor of COPI vesicle transport and Golgi disruptor, GCA, for its effect on viability and Golgi shape. Significant changes in Golgi morphology and cell survival became apparent only with much higher concentrations (micromolar range) compared with AMF-26 or BFA, the latter of which in addition to GBF1 can also inhibit two other large GEFs, BIG1 and BIG2 ( Figure 2D,E) . Nonetheless, the effect on both Golgi integrity and viability were dose-dependent following the pattern of AMF-26 and BFA.
| Relationships between Golgi complex integrity, viability and protein secretion
The analysis of several phenotypes-cell proliferation, Golgi integrity . Cell viability was determined using the CTB assay (CTB, blue color, left Y axis; survival ratios were derived from experiment presented in Figure 1A ), secretory activity was based on Gaussia luciferase measurement in the cell SN (GLuc, red color, right Y axis; secretion ratios were derived from experiments presented in Figures 2C and S2D) , and Golgi area data were derived from the analysis of immunofluorescent images for the Golgi marker GM130 (X axis; Golgi area ratios were derived from experiments presented in Figures 2A and S2B ). Spearman correlation was calculated after averaging measurements from 3 wells per compound concentration for CTB and GLuc parameters versus Golgi area changes. Displayed rho values indicate negative correlations between cell viability (CTB) and Golgi area (R, blue color) or cell secretion (GLuc) and Golgi area (R, red color) in response to AMF-26, BFA or GCA. All rho values except for # (.05 < p < .5) are statistically significant (p < .005).
FIGURE 4
Effect of ARF GTPases on cell viability and Golgi morphology following treatment with AMF-26 and BFA. A, 786-0, HeLa, A549, MCF7 and PANC1 cells were treated for 24 hours with vehicle (DMSO) or 150 nM AMF-26 and BFA, respectively. Cells were lysed in RIPA buffer, and protein samples were separated by SDS-PAGE before immunoblotting with the indicated antibodies. The anti-pan ARF antibody (1D9) recognizes all expressed ARF isoforms and is used to assess total ARF levels. The ARF1 and ARF5 blots were stripped and reprobed with pan ARF or ARF4 antibodies, respectively. B, A549 cells with stable overexpression of each of the 5 ARF isoforms Myc-tagged at the Cterminus or a control protein (Myc-Rap2a) were treated for 72 hours (viability assay) or 2 hours (immunofluorescence) with the AMF26/BFA concentrations shown. Expression levels of all overexpressed proteins are validated by Western blotting. Cell viability was measured by the CTB assay, and Golgi morphology was quantified by immunofluorescent staining using the cis-Golgi marker GM130. Survival ratios and Golgi areas in response to AMF-26 or BFA were calculated relative to the DMSO vehicle control. One of two representative experiments is shown; 3 different wells with on average 1000 cells were analyzed per condition and genotype. Student's two-tailed t test was used for statistical analysis. Asterisks represent statistically significant differences compared to the control Myc-Rap2a cell line, *p < .05, **p < .001. Error bars represent SD. C, Representative images of A549 cells stably overexpressing different ARF isoforms or the control protein Rap2a are shown, which were either left untreated or treated for 2 hours with 1000 nM AMF-26, or 40 nM BFA and stained for the Golgi GM130 marker (green) and Hoechst (blue). Cells overexpressing ARF1 and ARF5 show preserved Golgi integrity upon treatment with both AMF-26 and BFA. Scale bar: 20 μm. to the initiation of rather than being the result of ongoing apoptosis. 41 Thus, modulation of Golgi homeostasis with pharmacological compounds might have therapeutic potential to alleviate several pathologies as mentioned above.
We have tested more than a dozen human cancer cell lines for effects of AMF-26 and BFA on cell survival, and examined four cell lines in more detail by also analyzing secretory stress markers, Golgi integrity and protein secretion. AMF-26 treatment entails growthinhibitory profiles in cells closely resembling those of BFA but is less potent, which on one hand might be due to its reduced binding affinity to the ARF-GBF1 complex compared to BFA and on the other to AMF-26's inability to efficiently target the two other large ARF GEFs, BIG1 and BIG2, as suggested by our findings ( Figure 1D ). Although which might further explain its antineoplastic properties. Nonetheless, it is not clear whether AMF-26's pharmacokinetic properties including its metabolic stability significantly differ from BFA.
We used AMF-26 and BFA to assess whether a possible functional relationship exists between the degree of Golgi dispersal and cell viability/drug sensitivity or secretion, respectively. Significant correlations between these parameters were found both with AMF-26
and BFA in several cancer cell lines indicating that their mechanism of cell killing might be associated with disrupted Golgi morphology.
Corroborating these results, a similar association of Golgi dispersal and viability was found with GCA, another Golgi-fragmenting compound. It was previously reported that AG1478/Tyrphostin, another ARF1-GBF1 inhibitor, which induces Golgi disassembly, has significantly lower cytotoxicity than BFA. 9 Besides acting as uncompetitive inhibitor of ARF1-GBF1, BFA is known to cause ADP-ribosylation of BARS/CTBP1 and GAPDH, the former of which regulates Golgi tubule fission. [61] [62] [63] Whether these effects of BFA contribute to its conserved oligomeric complex (COG), 66 or Rab1. 53 Thus, sensitivity to AMF-26 and BFA will be determined by a combination of several factors. Notwithstanding this premise, and while we cannot exclude ARF1-independent effects, we show here that enhanced ARF1 expression is of central importance for cells to rectify AMF-26-and BFAinduced toxicity probably through titration of these compounds.
Rearrangement or partial disassembly of the Golgi ribbon and cisternae, however, does not mean by default that the Golgi loses its elemental protein-and lipid-processing and -modifying capabilities, which is also reflected by distinct Golgi complex organizations in different organisms. While one could be inclined to consider scattering of Golgi membranes synonymous with compromised functionality and incompatible with cell survival, this does not have to be necessarily the case. In fact even survival benefits for cancer cells such as increased metastatic capabilities could be associated with this phenotype. 44, 67 Moreover, Golgi fragmentation caused by DNA damaging agents appears to be an adaptive process important for enhanced survival, because prevention of this phenotype markedly reduced colony formation. 13 Depending on the stimulus and cellular context, Golgi unstacking might lead to accelerated or decreased transport of cargo to the plasma membrane concomitant with altered glycosylation and sorting. 46, 68, 69 In future, it will be essential to gain more 
| Cell lines and culture
All cell lines were obtained from ATCC and maintained in high-glucose (25 mM), pyruvate-free DMEM (Invitrogen), containing L-Glutamine, supplemented with 200 mg/mL penicillin, 100 mg/mL streptomycin sulfate and 10% heat inactivated fetal serum (IFS) (Invitrogen).
| Plasmids and cloning
Cloning of ARF1myc, ARF4myc and ARF5myc was described previously. 
| Gaussia luciferase assay

| Image processing and feature extraction
Image processing and data analysis was done using KNIME software. 71 Segmentation and feature extraction was performed similarly to previous work. 72, 73 Nuclei were segmented using an Otsu thresholding method. 74 Next, nuclei were extended to the border of the cell body using a Voronoi algorithm set to stop when the intensity dropped below a defined threshold. The vesicles composing the Golgi apparatus were identified with an Otsu global thresholding method 74 combined with a Bersen local thresholding method. 75 The structures identified with this method were then mapped back to their corresponding cell using the predefined cellular masks.
| Statistical analysis
Statistical analysis was performed based on triplicates using Student's two-tailed t test. Spearman rho values were calculated using Excel This work was generously supported by Merck KGaA.
